Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3
Open Access
- 23 July 2007
- journal article
- Published by Wiley in Parasite Immunology
- Vol. 29 (8) , 387-394
- https://doi.org/10.1111/j.1365-3024.2007.00951.x
Abstract
Many studies on the role of merozoite surface protein 3 (MSP3) in immunity against malaria have focused on a conserved section of MSP3. New evidence suggests that polymorphic sequences within MSP3 are under immune selection. We report a detailed analysis of naturally-acquired antibodies to allele-specific and conserved parts of MSP3 in a Kenyan cohort. Indirect and competition ELISA to heterologous recombinant MSP3 proteins were used for antibody assays, and parasites were genotyped for msp3 alleles. Antibody reactivity to allele-specific and conserved epitopes of MSP3 was heterogenous between individuals. Overall, the prevalence of allele-specific antibody reactivity was significantly higher (3D7-specific 54%, K1-specific 41%) than that to a recombinant protein representing a conserved portion of C-terminal MSP3 (24%, P < 0·01). The most abundant IgG subclass was IgG3, followed by IgG1. Allele-specific reactivity to the K1-type of MSP3 was associated with a lower risk of clinical malaria episodes during a 6-month follow-up in individuals who were parasitized at the start of the malaria transmission season (Relative risk 0·41 with 95% confidence interval 0·20–0·81, P = 0·011). The potential importance of allele-specific immunity to MSP3 should be considered in addition to immunity to conserved epitopes, in the development of an MSP3 malaria vaccine.Keywords
This publication has 39 references indexed in Scilit:
- A Malaria Vaccine That Elicits in Humans Antibodies Able to Kill Plasmodium falciparumPLoS Medicine, 2005
- High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal KenyaVaccine, 2005
- Case Definitions of Clinical Malaria under Different Transmission Conditions in Kilifi District, KenyaThe Journal of Infectious Diseases, 2005
- The global distribution of clinical episodes of Plasmodium falciparum malariaNature, 2005
- Immunization of Saimiri sciureus Monkeys with a Recombinant Hybrid Protein Derived from the Plasmodium falciparum Antigen Glutamate-Rich Protein and Merozoite Surface Protein 3 Can Induce Partial Protection with Freund and Montanide ISA720 AdjuvantsClinical and Vaccine Immunology, 2005
- Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malariaVaccine, 2004
- Malaria vaccines: if at first you don't succeed…Trends in Parasitology, 2004
- Association between Protection against Clinical Malaria and Antibodies to Merozoite Surface Antigens in an Area of Hyperendemicity in Myanmar: Complementarity between Responses to Merozoite Surface Protein 3 and the 220-Kilodalton Glutamate-Rich ProteinInfection and Immunity, 2004
- Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteersVaccine, 2000
- Malaria-a neglected disease?Parasitology, 1992